Dose-response effects of estrogen and tamoxifen upon methamphetamine- induced behavioral responses and neurotoxicity of the nigrostriatal dopaminergic system in female mice

Neuroendocrinology

Volumn 79, Issue 6, 2004, Pages 305-316

  Mickley, Katherine R ^a   Dluzen, Dean E ^a  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

Catecholamines; Methamphetamine; Mice; Neurodegeneration; Neuroprotection; Parkinson's disease; Selective estrogen receptor modulators

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; ESTRADIOL BENZOATE; METHAMPHETAMINE; NEUROPROTECTIVE AGENT; TAMOXIFEN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOASSAY; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG EFFECT; DRUG RESPONSE; DRUG SCREENING; FEMALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STEREOTYPY; UTERUS WEIGHT;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; METHAMPHETAMINE; MICE; MOVEMENT; NEOSTRIATUM; NEUROTOXINS; ORGAN SIZE; OVARIECTOMY; STEREOTYPED BEHAVIOR; SUBSTANTIA NIGRA; TAMOXIFEN; UTERUS;

EID: 4444220921     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079710     Document Type: Article

References (54)

1. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Meunter MD: An examination of male-female differences in progression and mortality of Parkinson's disease. Neurology 1990;40:763-766.
2. Dluzen DE, Disshon KA, McDermott JL: Estrogen as a modulator of striatal dopaminergic neurotoxicity; in Marwah J, Teitelbaum H (eds): Recent Advances in Neurodegenerative Disorders. Scottsdale, Prominent Press, 1998, vol 1, pp 149-192.
3. Baldereschi M, Dicarlo A, Rocca A, Vanni P, Maggi S, Perissinotto E, Grigoletto F, Amaducci L, Inzitari D, for the ILSA Working Group: Parkinson's disease and parkinsonism in a longitudinal study. Two-fold higher incidence in men. Neurology 2000;55:1358-1363.
4. Schrag A, Ben-Shlomo Y, Quinn NP: Crosssectional prevalence survey of idiopathic Parkinson's disease and parkinsonism in London. Br Med J 2001;321:21-22.
5. Swerdlow RH, Parker WD, Currie LJ, Bennet JP, Harrison MB, Trugman JM, Wooten GF: Gender ratio differences between Parkinson's disease patients and their affected relatives. Parkinsonism Relat Disord 2001;7:129-136.
6. Toung TJ, Traystman RJ, Hurn PD: Estrogen-mediated neuroprotection after experimental strokes in male rats. Stroke 1998;29:1666-1670.
7. Fukuda K, Yao H, Ibayashi S, Nakahara T, Uchimura H, Fujishima M, Hall ED: Ovariectomy exacerbates and estrogen replacement attenuates phototrombotic focal ischemic brain injury in rats. Stroke 2000;31:155-160.
8. Liao S, Chen W, Kuo J, Chen C: Association of serum estrogen level and ischemic neuroprotection in female rats. Neurosci Lett 2001;297:159-166.
9. Wise PM, Dubal DB, Wilson ME, Rau SW, Bottner M, Rosewell KL: Estradiol is a protective factor in the adult and aging brain: Understanding of mechanisms derived from in vivo and in vitro studies. Brain Res Rev 2001;37:313-319.
10. Granholm AC: Oestrogen and nerve growth factor - neuroprotection and repair in Alzheimer's disease. Expert Opin Invest drugs 2000;9:685-694.
11. Miller MM, Monjan AA, Buckholtz NS: Estrogen replacement therapy for the potential treatment or prevention of Alzheimer's disease. Ann NY Acad Sci 2001;949:223-234.
12. Owens CT: Estrogen replacement therapy for Alzheimer's disease in postmenopausal women. Ann Pharmacother 2002;37:1273-1281.
13. Dluzen DE, McDermott JL, Liu B: Estrogen alters MPTP-induced neurotoxicity in female mice: Effects on striatal dopamine concentrations and release. J Neurochem 1996;66:658-666.
14. Dluzen DE, McDermott JL, Liu B: Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/Bl mice. Neurotoxicol Teratol 1996;18:603-606.
15. Miller D, Ali SF, O'Callaghan JP, Laws SC: The impact of gender and estrogen on striatal dopamine neurotoxicity. Ann NY Acad Sci 1998;844:153-165.
16. Grandbois M, Morissette M, Callier S, Di Paolo T: Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice. NeuroReport 2000;11:343-346.
17. Callier S, Morissette M, Grandbois M, Pelaprat D, Di Paolo T: Neuroprotective properties of 17beta-estradiol, progesterone and raloxifene in MPTP C57Bl/6 mice. Synapse 2001;41:131-138.
18. Tomas-Camardiel M, Sanchez-Hidalgo MC, Sanchez Del Pino MJ, Navarro A, Machado A, Cano J: Comparative study of the neuroprotective effect of dehydroepiandrosterone and 17β-estradiol against 1-methyl-4-phenylpyridium toxicity on rat striatum. Neuroscience 2002;109:569-584.
19. Ramirez AD, Liu X, Menniti FS: Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice. Neuroendocrinology 2003;77:223-231.
20. Dluzen DE, McDermott JL: Neuroprotective role of estrogen upon methamphetamine and related neurotoxins within the nigrostriatal dopaminergic system. Ann NY Acad Sci 2000;914:112-126.
21. Yu L, Liao P-C: Estrogen and progesterone distinctly modulate methamphetamine-induced dopamine and serotonin depletions in C57Bl/6J mice. J Neural Transm 2000;107:1139-1147.
22. Gao X, Dluzen E: Tamoxifen abolishes estrogen's neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Neuroscience 2001;103:385-394.
23. Dluzen DE, McDermott JL: Estrogen, antiestrogen and gender differences in methamphetamine neurotoxicity. Ann NY Acad Sci 2002;965:136-156.
24. Yu L, Kuo Y, Cherng CG, Chen H-H, Hsu C-H: Ovarian hormones do not attenuate methamphetamine-induced dopaminergic neurotoxicity in mice gonadectomized at 4 weeks postpartum. Neuroendocrinology 2002;75:282-287.
25. Dluzen DE: Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine. Brain Res 1997;767:340-344.
26. Dluzen DE: Neuroprotective effects of estrogen upon the nigrostriatal dopaminergic system. J Neurocytol 2000;29:387-399.
27. Dluzen E, McDermott JL: Gender differences in the neurotoxicity of the nigrostriatal dopaminergic system: Implications for Parkinson's disease. J Gend Specif Med 2000;3:36-42.
28. Dluzen DE, Horstink MWIM: Estrogen as a neuroprotectant of the nigrostriatal dopaminergic system: Laboratory and clinical considerations. Endocrine 2003;21:67-75.
29. Horstink MWIM, Strijks E, Dluzen DE: Estrogen and Parkinson's disease. Adv Neurol 2003;91:107-114.
30. Dluzen DE, McDermott JL, Anderson LI: Tamoxifen eliminates estrogen's neuroprotective effect upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system. Neurotoxicol Res 2001;3:291-300.
31. Obata T, Kubota S: Protective effect of tamoxifen on 1-methyl-4- phenylpyridine-induced hydroxyl radical generation in the rat striatum. Neurosci Lett 2001;308:87-90.
32. Dluzen DE, McDermott JL, Anderson LI: Tamoxifen diminishes methamphetamine-induced striatal dopamine depletion in intact female and male mice. J Neuroendocrin 2001;13:618-624.
33. Gao X, Dluzen DE: The effect of testosterone upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Brain Res 2001;892:63-69.
34. Gajjar M, Anderson LI, Dluzen DE: Acute effects of estrogen upon methamphetamine induced neurotoxicity of the nigrostriatal dopaminergic system. J Neural Transm 2003;110:1215-1224.
35. McDermott JL, Anderson LI, Dluzen DE: Tamoxifen treatment of ovariectomized mice alters dopamine release from striatal tissue fragments superfused in vitro. Brain Res 1995;698:248-252.
36. Dluzen DE, Anderson LI, Pilati CF: Methamphetamine-gonadal steroid hormone interactions: Effects upon acute toxicity and striatal dopamine depletions. Neurotoxicol Teratol 2002;24:267-273.
37. Feder HH: Estrous cyclicity in mammals; in Adler NT (ed): Neuroendocrinology of Reproduction - Physiology and Behavior. New York, Plenum Press, 1981, pp 279-348.
38. Vongher JM, Frye CA: Progesterone in conjunction with estradiol has neuroprotective effects in an animal model of neurodegeneration. Pharmacol Biochem Behav 1999;64:777-785.
39. Yu L, Liao P-C: Sexual differences and estrous cycle in methamphetamine-induced dopamine and serotonin depletions in the striatum of mice. J Neural Transm 2000;107:419-427.
40. Datla KP, Murray HE, Pillai A, Gillies GE, Dexter DT: Differences in dopaminergic neuroprotective effects of estrogen during estrous cycle. NeuroReport 2003;14:47-50.
41. Myers RE, Anderson LI, Dluzen DE: Estrogen, but not testosterone, attenuates methamphetamine-evoked dopamine output from superfused striatal tissue of female and male mice. Neuropharmacology 2003;44:624-632.
42. Cyr M, Calon F, Morissette M, Grandbois M, Di Paolo T, Callier S: Drugs with estrogen-like potency and brain activity: Potential therapeutic application for the CNS. Curr Pharm Res 2000;6:1287-1312.
43. 3 dopamine receptors in rat forebrain. Neuroendocrinology 2002;76:214-222.
44. Miller CC, Holmes PV, Edwards GL: Area postrema lesions elevate NPY levels and decrease anxiety-related behaviors in rats. Physiol Behav 2002;77:135-140.
45. Sullivan GM, Apergis J, Gorman JM, LeDoux JE: Rodent doxapram model of panic attack: Behavioral effects and c-Fos immunoreactivity in the amygdala. Biol Psychiat 2003;53:863-870.
46. Vendruscolo LF, Takahashi RN, Bruske GR, Ramos A: Evaluation of the anxiolytic-like effect of NKP608, a NK1-receptor antagonist, in two rat strains that differ in anxiety-related behaviors. Psychopharmacology 2003;170:287-293.
47. Sato M, Rippy MK, Bryant U: Raloxifene, tamoxifen, nafoxidine or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 1996;10:905-912.
48. Kimelberg HK, Feustel PJ, Paquette J, Boulos A, Keller RW Jr, Tranmer BI: Acute treatment with tamoxifen reduces ischemic damage following cerebral artery occlusion. NeuroReport 2000;11:2675-2679.
49. Dhandapani KM, Brann DW: Neuroprotective effects of estrogen and tamoxifen in vitro. Endocrine 2003;21:59-66.
50. Kimelberg HK, Jin Y, Charniga C, Feustel PJ: Neuroprotective activity of tamoxifen in permanent focal ischemia. J Neurosurg 2003;99:138-142.
51. Shy H, Malaiyandi L, Timiras P: Protective action of 17beta-estradiol and tamoxifen on glutamate toxicity in glial cells. Int J Develop Neurosci 2000;18:289-297.
52. Hoyt KR, McLaughlin BA, Higgins DS Jr, Reynolds IJ: Inhibition of glutamate-induced mitochondrial depolarization by tamoxifen in cultured neurons. J Pharmacol Exp Ther 2000;293:480-486.
53. Dluzen DE, McDermott JL: Gender differences in the neurotoxicity of the nigrostriatal dopaminergic system: Implications for Parkinson's disease. J Gend Specif Med 2000;3:36-42.
54. Dluzen DE, Tweed C, Anderson LI, Laping NJ: Gender differences in methamphetamine-induced mRNA associated with neurodegeneration in the mouse nigrostriatal dopaminergic system. Neuroendocrinology 2003;77:232-238.